Summary
AbbVie Inc. reported its third-quarter and nine-month results for the period ending September 30, 2013, marking its first full year as an independent, publicly traded company following its spin-off from Abbott Laboratories on January 1, 2013. The company demonstrated solid top-line growth, with net sales increasing by 3% and 4% for the three and nine months, respectively, driven primarily by the strong performance of its flagship product, HUMIRA. Despite facing patent expirations for key products like TriCor and Niaspan, AbbVie's diversified portfolio and ongoing R&D efforts, particularly in expanding HUMIRA's indications and developing new therapies for chronic diseases, position it for continued growth. The company also managed its expenses effectively, with R&D spending seeing a decrease due to prior-year charges, though SG&A increased to support growth and the costs associated with operating as a standalone entity.
Financial Highlights
50 data points| Revenue | $4.66B |
| Cost of Revenue | $1.09B |
| Gross Profit | $3.57B |
| SG&A Expenses | $1.26B |
| Operating Expenses | $3.29B |
| Operating Income | $1.37B |
| Interest Expense | $75.00M |
| Net Income | $964.00M |
| EPS (Basic) | $0.60 |
| EPS (Diluted) | $0.60 |
| Shares Outstanding (Basic) | 1.59B |
| Shares Outstanding (Diluted) | 1.60B |
Key Highlights
- 1Net sales increased by 3% to $4.66 billion for the third quarter and 4% to $13.68 billion for the first nine months of 2013, demonstrating consistent revenue growth.
- 2HUMIRA remained the primary growth driver, with sales up 19% to $2.77 billion in Q3 and 16% to $7.62 billion for the nine months, reflecting strong performance across multiple indications and geographies.
- 3The company incurred $220 million in acquired in-process R&D expenses in Q3 2013, including significant collaboration agreements with Ablynx NV and Galapagos NV, indicating continued investment in pipeline development.
- 4Operating earnings decreased by 14% to $1.37 billion in Q3 2013, largely due to higher SG&A expenses and acquired in-process R&D, despite revenue growth.
- 5Net earnings saw a significant decrease to $964 million in Q3 2013 compared to $1.59 billion in Q3 2012, impacted by increased operating costs and the absence of a significant tax benefit recorded in the prior year.
- 6AbbVie maintained a strong liquidity position, with cash and cash equivalents and short-term investments totaling $9.60 billion at September 30, 2013.
- 7The company declared and paid a quarterly cash dividend of $0.40 per share in Q3 2013 and authorized a $1.5 billion stock repurchase program, signaling a commitment to returning capital to shareholders.